Pfizer

  • user warning: Table './intheclinic/captcha_sessions' is marked as crashed and should be repaired query: INSERT into captcha_sessions (uid, sid, ip_address, timestamp, form_id, solution, status, attempts) VALUES (0, 'v4h2nre7u5d8qmhgk9f9ltdjv7', '38.107.191.116', 1268350202, 'user_login_block', 'undefined', 0, 0) in /persistent/html/sites/all/modules/captcha/captcha.inc on line 92.
  • user warning: Table './intheclinic/captcha_sessions' is marked as crashed and should be repaired query: SELECT status FROM captcha_sessions WHERE csid = 0 in /persistent/html/sites/all/modules/captcha/captcha.inc on line 112.
  • user warning: Table './intheclinic/captcha_sessions' is marked as crashed and should be repaired query: SELECT status FROM captcha_sessions WHERE csid = 0 in /persistent/html/sites/all/modules/captcha/captcha.inc on line 112.
  • user warning: Table './intheclinic/captcha_sessions' is marked as crashed and should be repaired query: UPDATE captcha_sessions SET timestamp=1268350202, solution='1' WHERE csid=0 in /persistent/html/sites/all/modules/captcha/captcha.inc on line 104.

A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis

Trial phase: 
Phase I
Recruitment status: 
Completed
  1. Quantify how much PD-0332334 is removed from the blood with hemodialysis
  2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments.
  3. Investigate the safety and tolerability of a single dose of PD-0332334 in subjects receiving hemodialysis.
Background information
Trial ID: 
NCT00730145
Other unique IDs: 
A5361032
Official title: 

A Phase I, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD-0332334 In Subjects Receiving Chronic Hemodialysis

Detailed description: 

Assess the elimination of PD-0332334 from the blood with hemodialysis

Number to be enrolled: 
8 patients

Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors

Trial phase: 
Phase I
Recruitment status: 
Recruiting

The study is being conducted to determine the maximum tolerated dose, overall safety and tolerability profile, and pharmacokinetic profile of CP-751,871 and sunitinib when given in combination with advanced solid tumors.

Background information
Trial ID: 
NCT00729833
Other unique IDs: 
A4021024
Official title: 

Phase 1, Open Label, Sequential Cohort, Dose Escalation Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors

Detailed description: 

 

Number to be enrolled: 
45 patients

Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome

Trial phase: 
Phase IV
Recruitment status: 
Recruiting

This present study is specifically designed to examine the efficacy and safety of a high pre-treatment dose of atorvastatin in Asian patients with NSTE-ACS in China and the Republic of Korea, by using a treatment paradigm similar to that employed in the ARMYDA-ACS study.

Background information
Trial ID: 
NCT00728988
Other unique IDs: 
A2581161
Official title: 

A Prospective Randomized, Open-Label, Parallel-Group Comparative Study: Atorvastatin Pre-Treatment Versus Usual Care In Asian Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention

Detailed description: 

 

Number to be enrolled: 
350 patients
Acronym: 
ALPACS

Assessing Prevalence Of Beta Lactamase Production From Clinical Isolates Of Hospitalized Patients And Comparison Of Antibiotic Susceptibility Patterns

Trial phase: 
Phase 0
Recruitment status: 
Recruiting

EGAST 2008 is a prospective, non interventional, multicentric study (approximately 2000 isolates from 15- 20 sites). Objectives:

  • Comparison of antimicrobial susceptibility using disc-diffusion method
  • Assessing prevalence of beta-lactamase producing strains among clinical isolates obtained from hospital in-patients

Background information
Trial ID: 
NCT00728624
Other unique IDs: 
A1891005
Official title: 

Expert Group On Antibiotic Susceptibility Testing [EGAST] 2008: A Non-Interventional, Multicenter In-Vitro Study To Evaluate The Prevalence Of Beta-Lactamase Producing Strains Among Clinical Isolates Obtained From Hospital In-Patients And Comparison Of An

Detailed description: 

 

Number to be enrolled: 
2000 patients
Acronym: 
EGAST 2008

A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients

Trial phase: 
Phase I
Recruitment status: 
Recruiting

Research in test tubes suggests that may affect cytochrome P450 2D6 (CYP2D6), an important enzyme that is responsible for eliminating many drugs that cancer patients need to take, including dextromethorphan. The purpose of this study is to test the impact of PF-00299804 on the activity of CYP2D6, and how the human body handles dextromethorphan.

Background information
Trial ID: 
NCT00728468
Other unique IDs: 
A7471014
Official title: 

A Phase 1, Open Label, Single Arm Trial To Evaluate The Effect Of PF- 00299804 On The Pharmacokinetics Of Dextromethorphan In Patients With Advanced Malignant Solid Tumors

Detailed description: 

 

Number to be enrolled: 
18 patients

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Trial phase: 
Phase I
Recruitment status: 
Recruiting

This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in prior studies, and this study is to establish the safety and efficacy of the combination

Background information
Trial ID: 
NCT00728390
Other unique IDs: 
A7471004
Official title: 

Phase 1 Targeted Combination Trial Of PF-00299804 And CP-751,871 In Patients With Advanced Solid Tumors

Detailed description: 

 

Number to be enrolled: 
45 patients

A Study In Patients With Advanced Solid Tumor

Trial phase: 
Phase I
Recruitment status: 
Active, not recruiting

This study designed to evaluate the pharmacokinetics and safety of AG-013736 at single doses and multiple doses

Background information
Trial ID: 
NCT00726752
Other unique IDs: 
A4061044
Official title: 

A Phase 1 Study In Patients With Advanced Solid Tumor To Evaluate The Pharmacokinetics And Safety Of AG-013736 At Single Doses Of 5 mg, 7 mg And 10 mg, And At Multiple Doses

Detailed description: 

 

Number to be enrolled: 
6 patients

A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation

Trial phase: 
Phase III
Recruitment status: 
Recruiting

This local registration study is to confirm the hypothesis of the efficacy, tolerability and safety of ziprasidone IM (intramuscular) in the Chinese population with agitation in schizophrenia

Background information
Trial ID: 
NCT00723606
Other unique IDs: 
A1281152
Official title: 

A Randomized, Open Label, Rater Blind, Flexible Dose Multi-Center Study Comparing The Efficacy And Safety Of Intramuscular Ziprasidone With Haloperidol For Three Days In Patients With Agitation Of Schizophrenia

Detailed description: 

 

Number to be enrolled: 
364 patients

PF-04191834 Single Dose Bronchodilatory Study In Asthma.

Trial phase: 
Phase II
Recruitment status: 
Recruiting

Study to determine the bronchodilatory effects of PF-04191834 compared with zileuton in patients with asthma

Background information
Trial ID: 
NCT00723021
Other unique IDs: 
B0041002
Official title: 

A Phase 2a, Randomised, Double-Blind (3rd Party Open), Double-Dummy, Placebo And Active Controlled 5-Way Crossover Study To Assess The Bronchodilatory Action, Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04191834 In Asthmatic Patient

Detailed description: 

 

Number to be enrolled: 
15 patients
Syndicate content